Bristol Myers Squibb is working on contingency plans to “protect the continuity of supply” of medicine in preparation for draft US legislation seeking to restrict Chinese pharmaceutical companies over national security concerns, according to its finance chief.The Biosecure Act, introduced in the US Congress in January, would prohibit US companies receiving federal grant money from working with WuXi AppTec and any related entities. Three other Chinese companies are named in the draft legislation, including gene sequencing group BGI Genomics.
百时美施贵宝(Bristol Myers Squibb)的首席财务官表示，该公司正在制定“保护（药品）供应连续性”的应急预案，以求针对美国出于国家安全担忧对manbetx3.0 药企设限的立法草案做好准备。
您已阅读15%（640字），剩余85%（3694字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。